GVHD,Acute Clinical Trial
Official title:
CXC-chemokine Ligand 9 (CXCL9) and Endothelial Activation and Stress Index (EASIX) for Prediction of Acute Graft Versus Host Disease
The prediction of severe acute GVHD before it occurs is of high importance for ensuing clinical decisions and overall success of allogeneic SCT. The key immunologic signatures associated with clinical outcomes after different graft versus host disease prophylaxis methods or peripheral blood stem cell transplant are largely unknown.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT05855707 -
Wharton Jelly Mesenchymal Stromal Cells as GVHD Prophylaxis
|
Phase 1 | |
| Active, not recruiting |
NCT04522843 -
Analysis of Intestinal Defensin Expression in Acute GVHD
|
||
| Recruiting |
NCT05368181 -
MAP-guided Preemptive Therapy of aGvHD
|
Phase 2 | |
| Recruiting |
NCT05401955 -
Physiotherapy and Therapeutic Exercise Program in Graft-versus-host Disease (GvHD)
|
N/A | |
| Withdrawn |
NCT05443464 -
Mesenchymal Stem Cells (MSCs) for Steroid Refractory Acute GVHD (SR-aGVHD)
|
Phase 1 | |
| Not yet recruiting |
NCT06315309 -
Trial of 2 Step ATG for Acute GVHD Prevention Post Myeloablative Allogeneic Stem Cell Transplant
|
Phase 2 | |
| Terminated |
NCT04220632 -
A Study of IBI377 in Combination With Corticosteroids for the Treatment of First-Line Acute Graft-Versus-Host Disease
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04284904 -
Role of aGVHD Biomarkers on aGVHD Risks
|
||
| Not yet recruiting |
NCT06164288 -
Safety and Efficacy Study of hAESCs Therapy for aGVHD
|
Phase 1 | |
| Recruiting |
NCT06462365 -
Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
|
Phase 1 |